These findings suggest that targeting PRMT3 could suppress HCC tumor progression through cancer cell-intrinsic and cancer cell-extrinsic mechanisms (e.g., promoting T cell-mediated anti-tumor immunity). The gene discussed is PRMT3; the disease is cancer.